Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Dialysis patients often suffer from lower extremity artery disease (LEAD) due to arteriosclerosis, leading to amputations. LEAD patients also commonly have concomitant arteriosclerosis in the heart and cerebrovascular system, resulting in high mortality. Both Skin Perfusion Pressure (SPP) and Ankle-Brachial Index (ABI) have been reported as independent risk factors for mortality in these patients. To analyze the clinical findings, prognosis, and the correlation between SPP and ABI values in hospitalized dialysis patients with SPP ≤ 40 mmHg or ABI ≤ 0.9, which are critical thresholds for revascularization.
Subjects: A total of 230 chronic hemodialysis patients (278 admissions) hospitalized at our institution between January and December 2023 were analyzed. Among them, 38 patients had SPP testing, and 98 had ABI testing.
Methods: SPP was measured using the PAD4000 (SPP-K1, Kaneka Medix, Japan). Patients with SPP ≤ 40 mmHg (Group A, n=21) were compared with those with SPP ≥ 41 mmHg (Group B, n=17) for correlation with LEAD, prognosis (mortality within 1 year of SPP measurement), and clinical characteristics. ABI was measured using the BP-203RPEIII (Fukuda Denshi, Japan). Patients with ABI < 0.9 (Group I, n=33) were compared with those with ABI ≥ 0.9 (Group II, n=65) for correlation with mortality, causes of death, and SPP values.
Among the hospitalized patients, 98 (43%) had LEAD. The SPP test was performed on 14% (40/278) of the patients, with a mean age of 78.3 years in Group A and 74.0 years in Group B. The male-to-female ratio was 14:7 in Group A and 12:5 in Group B. The underlying disease for dialysis initiation was diabetes in 10 cases of Group A and 10 cases of Group B, and nephrosclerosis in 4 cases of each group. The average dialysis duration was 5.97 ± 6.8 years in Group A and 5.17 ± 6.7 years in Group B. Mortality within 1 year after SPP measurement was 62% (13/21) in Group A and 18% (3/17) in Group B, with a significant difference (independent t-test, p=0.0181). Group A showed a higher number of deaths due to infections compared to Group B (7 vs. 1), but this was not statistically significant. No significant differences were observed between the 13 deaths and 8 survivors in Group A in terms of mean age, gender, underlying disease, dialysis history, corrected serum calcium, phosphate, CRP levels, white blood cell count, or hemoglobin levels. Serum albumin was significantly lower in the deceased (Group A: 2.32 ± 0.49 g/dL, Group B: 3.0 ± 0.35 g/dL, independent t-test, t=-3.50, p=0.0025). ABI < 0.9 was associated with significantly higher mortality (Group A: 30%, Group B: 9%, Chi-square test: p=0.0156). Among the 21 patients who underwent both SPP and ABI testing, a significant correlation was found (regression: SPP = 2.548 + 0.3056 × ABI, p=0.013).
LEAD is common among chronic dialysis patients. The 1-year mortality rate for patients with SPP ≤ 40 mmHg was high. Low serum albumin levels were significantly associated with mortality, emphasizing the need for proper nutrition. For dialysis patients with LEAD, especially those with either SPP ≥ 41 mmHg or ABI ≥ 0.9, or both, close inter-facility collaboration in dialysis management, wound care, revascularization, and surgery is essential.
